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Abstract
Background:  Ethambutol (EMB) is a first-line drug for the treatment of tuberculosis (TB).
Resistance to EMB in Mycobacterium tuberculosis isolates is mediated by mutations in several genes
involved in arabinan synthesis notably three emb  (arabinosyl transferase) and iniA  (isoniazid-
inducible) genes. Most epidemiologically unrelated EMB-resistant M. tuberculosis strains contain
mutations at embB codons 306, 406 and 497, embC-embA intergenic region (IGR) and iniA codon
501 (iniA501).
Objective:  To develop a more comprehensive molecular screen for EMB-resistance
detectioamong epidemiologically unrelated EMB-resistant M. tuberculosis strains previously analyzed
for embB codon 306, 406 and 497 mutations by including analysis of mutations at iniA501 and in
embC-embA IGR.
Methods: Fifty consecutive and phenotypically documented EMB-resistant and 25 pansusceptible
M. tuberculosis strains isolated from 75 different TB patients over a four-year period in Kuwait were
analyzed. Mutations at iniA501 were detected by PCR amplification followed by restriction fragment
length polymorphism (RFLP) patterns generated with Hpy 99 I. Direct DNA sequencing was used
to confirm RFLP results and for detecting mutations in embC-embA IGR.
Results: Nearly same number of EMB-resistant M. tuberculosis strains were resistant to EMB alone
and EMB together with additional resistance to rifampicin and isoniazid (9 of 50, 18% and 11 of 50,
22%, respectively). All the 25 pansusceptible strains contained wild-type sequences at iniA501 and
in embC-embA IGR. The analysis of 50 EMB-resistant M. tuberculosis isolates showed that only one
strain contained a mutated iniA501 while no mutation was detected in embC-embA IGR in any of
the isolate.
Conclusion: Analysis of iniA501 and embC-embA IGR in epidemiologically unrelated EMB-resistant
M. tuberculosis isolates in Kuwait indicate that mutations at these locations occur very infrequently
and their inclusion for the development of a comprehensive molecular screen will make only minor
contribution towards rapid EMB resistance detection.
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Background
The tuberculosis (TB) epidemic continues unabated.
Despite intense efforts made over the past two decades,
the morbidity and mortality associated with TB remain
high, with 8 million active disease cases and 2 million
deaths occurring worldwide every year [1,2]. Two factors,
co-infection with human immunodeficiency virus (HIV)
and increasing incidence of infections with drug-resistant
strains of Mycobacterium tuberculosis are steadily worsening
the problem of TB [3,4]. The latest World Health Organi-
zation (WHO)-sponsored study showed that drug-resist-
ant TB among new cases is prevalent in 74 of 77 (96%)
settings or countries with resistance to at least one anti-TB
drug varying from 0% in some rich, developed countries
to >30% in several developing countries [4]. Infections
with drug-resistant, particularly multidrug-resistant
(MDR) (resistant to at least rifampicin and isoniazid)
strains of M. tuberculosis (MDR-TB) are associated with
higher mortality [4,5]. Molecular methods for rapidly
identifying drug-resistant strains of M. tuberculosis are
urgently needed to avoid inadequate treatment since phe-
notypic drug susceptibility testing by radiometric method
requires 4–14 days after the primary culture has been iso-
lated [6]. A simple and rapid line probe assay has been
developed recently for detection of resistance of M. tuber-
culosis to rifampicin and isoniazid (MDR-TB) in cultured
isolates and clinical samples [7]
Ethambutol (EMB), an arabinose analogue, is a bacteri-
cidal, first-line drug for the treatment of TB. The EMB is
often used, along with isoniazid, rifampicin and pyrazina-
mide, as an alternative to streptomycin, in the four-drug
regimens advocated by World Health Organization under
the directly observed chemotherapy short-course. Global
data on drug resistance patterns have shown that resist-
ance of M. tuberculosis to EMB in newly diagnosed as well
as previously treated cases is much less compared to strep-
tomycin [4,8]. Similar pattern is also noted in the rate of
resistance of M. tuberculosis isolates to EMB (1.98%) and
streptomycin (4.31%) in Kuwait [9]. Since resistance of
M. tuberculosis to EMB is also generally associated with
resistance to other anti-TB drugs [8,10], early detection of
resistance will not only abolish drug-associated adverse
reactions, particularly optic neuritis, it will also suggest
modifications in therapy regimens.
The mechanism of action and the molecular genetic basis
of resistance to EMB are complex and are not completely
defined. The enzymes participating in synthesis and
polymerization of cell wall arabinan are implicated as the
main target for EMB. These include three homologous
and membrane associated arabinosyltransferases encoded
by three contiguous genes, embC-embA-embB, isoniazid-
inducible genes particularly iniA, acyl carrier proteins and
regulatory proteins modulating their expression [11-13].
Mutations in embB  particularly involving codon 306
(embB306) and less frequently, codons 406 (embB406)
and 497 (embB497) have been identified as most com-
mon genetic alterations conferring resistance to EMB in
clinical M. tuberculosis isolates [11-14]. The frequency of
these mutations in EMB-resistant strains in some studies
has been reported to be ~70% [14-17]. However, in epide-
miologically unrelated strains, these mutations accounted
for EMB resistance in only around 30% EMB-resistant iso-
lates [13,18]. Only one study has so far detected muta-
tions in other emb  (embA  and  embC) or other genes
conferring resistance to EMB in epidemiologically unre-
lated EMB-resistant strains [13]. The data showed that,
mutations in embC-embA  intergenic region (IGR) (four
nucleotide positions), embA  (several codons) and iniA
(mainly codon 501, iniA501) occurred in ~30% EMB-
resistant strains while mutations in eight other genes were
either absent or occurred infrequently [13]. However, the
role of mutations in these loci in conferring resistance to
EMB remain unclear as these mutations, particularly in
embC-embA IGR, were found in isolates with other well-
characterized EMB resistance conferring mutations [13].
The TCG to TGG mutation at iniA501 most likely confers
resistance of M. tuberculosis to EMB as it alters the struc-
tural property of the encoded protein [13]. However, the
resistance conferring mechanism explaining the role of
mutations in embC-embA  IGR is not well characterized
and the paucity of information on the frequency of muta-
tions in embC-embA IGR in EMB-resistant M. tuberculosis
strains from different regions of the world makes it diffi-
cult to ascertain their exact role in conferring resistance to
EMB. The present study was carried out to detect the fre-
quency of mutations at iniA501 and in embC-embA IGR in
50 consecutive and epidemiologically unrelated EMB-
resistant M. tuberculosis strains that were analyzed previ-
ously for embB306, embB406 and embB497 mutations [18]
in an effort to develop a more comprehensive molecular
screen for EMB-resistance detection. The EMB-susceptible
isolates were also analyzed simultaneously to ensure that
such mutations are not present in EMB-susceptible
strains.
Materials and methods
EMB-resistant and -susceptible M. tuberculosis strains
A single TB control unit and the Kuwait National Tubercu-
losis Reference Laboratory (KNTRL) under the Ministry of
Health are responsible for the diagnosis and treatment of
all TB patients in Kuwait. Appropriate specimens from
suspected TB patients are sent to KNTRL for culture. All
active TB cases are diagnosed by culture and susceptibility
testing to first line anti-TB drugs is performed on all the
isolates identified as M. tuberculosis [19]. All the 50 EMB-
resistant  M. tuberculosis strains (KE1 to KE50) isolated
throughout Kuwait from 50 different TB patients during
2000 to 2003 were included in this study. The clinicalAnnals of Clinical Microbiology and Antimicrobials 2009, 8:2 http://www.ann-clinmicrob.com/content/8/1/2
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background and demographic data of patients yielding
EMB-resistant M. tuberculosis strains are shown in Table 1.
Repeat isolates were recovered from eight TB patients
within one to two months of isolation of the first isolate.
A total of 25 M. tuberculosis strains susceptible to all first-
line drugs (pansusceptible strains) were also included.
The isolation and identification of M. tuberculosis strains
from clinical specimens was performed using the myco-
bacterial growth indicator tube (MGIT) 960 system as
described previously [20]. The drug susceptibility testing
of  M. tuberculosis isolates was performed using the
BACTEC 460 TB system as reported earlier [6,21]. The iso-
lates were considered EMB resistant when bacterial
growth occurred at a concentration of 2.5 μg EMB per ml.
Resistance of all the isolates to isoniazid (0.1 μg/ml),
rifampicin (2 μg/ml) and streptomycin (2 μg/ml) was also
determined.
Sample preparation for PCR
The M. tuberculosis reference strain H37Rv was used as a
control in PCR-RFLP and DNA sequencing. The reference
strain and clinical EMB-resistant and pansusceptible M.
tuberculosis isolates were obtained as heat killed BACTEC
liquid cultures. One ml of BACTEC culture was heated
with 40 mg Chelex-100 (Sigma) at 95°C for 20 min fol-
lowed by centrifugation at 12,000 × g for 15 min and the
supernatant obtained was used as the source of genomic
DNA [22] for the amplification of various gene regions.
Primer design and PCR amplification
Two primer pairs were synthesized. One primer pair
(INIAF and INIAR) was used for the amplification of the
iniA gene (Genbank accession no. Z95324) region around
codon 501. Another primer pair (IGRF and IGRR) was
synthesized for the amplification of embC-embA  IGR
(Genbank accession no. AL123456) including nucleotide
positions that are mutated in EMB-resistant strains [13].
The DNA sequences of the primers, their positions on the
target genes and the expected size of the PCR products are
shown in Table 2.
The PCR amplification of the target DNA was carried out
in a final volume of 50 μl and contained 5 μl of 10× Per-
kin-Elmer PCR buffer, 10 pmol of the appropriate forward
(F) and reverse (R) primers (INIAF and INIAR or IGRF and
IGRR, Table 2), 2 μl of template DNA, 0.1 mM dNTPs, 2
units of AmpliTaq DNA polymerase (Perkin-Elmer) and
sterile distilled water. The cycling parameters were same as
described previously [22]. Following amplification, a por-
tion of the product (10 μl) was run on 2% agarose gels
[22] to confirm the amplification of a DNA fragment of
expected size. The remaining PCR product was purified by
using PCR purification columns (Qiagen) that were used
as instructed by the manufacturer. The purified amplicons
were used for further studies.
Detection of mutations at iniA501 by PCR-RFLP
The mutations at iniA501  were detected by restriction
digestion of amplicons obtained with primers INIAF and
INIAR with Hpy 99I as described previously [22]. Briefly,
the reaction mixture in a final volume of 25 μl contained
5 μl of the purified amplicon, 10.25 μl of sterile water,
6.25 μl of NE Buffer 4, 2.5 μl of 10× BSA and 1 μl (2 units)
of Hpy99 I (New England Biolabs). After incubation at
37°C for 1 h, the digested products were separated on
2.5% agarose gels. The amplicon from M. tuberculosis
H37Rv as well as M. tuberculosis strains containing TCG at
iniA501 (iniA501TCG) yield two fragments of 104 bp and
137 bp while the amplicon from isolates containing TGG
at  iniA501  (iniA501TGG) yield the original undigested
fragment of 241 bp [22]. The results of RFLP for some of
the isolates were confirmed by DNA sequencing. The
DNA sequencing was performed by using the cycle DNA
sequencing kit (DTCS CEQ2000, Beckman Coulter) as
described in detail previously [22]. Briefly, the reaction
mixtures in a final volume of 20 μl contained, 8.0 μl of
purified amplicon, 1.0 μl (3.2 pmol) of primer INIAF or
INIAR (Table 2) or an internal primer (INIAS, 5'-CGCT-
GGGCCGGATGGAATCGAA-3'), 8.0 μl of the pre-mix
reaction components supplied in the kit and 3.0 μl sterile
water. The cycling parameters were same as described pre-
viously [22]. Reactions products were precipitated and
loaded on the DNA sequencer as directed by the manufac-
turer (Beckman Coulter Model CEQ8000).
Detection of mutations in embC-embA IGR by DNA 
sequencing
The mutations at -11, -12, -16 and -43 positions (relative
to the translational start point of embA) in embC-embA IGR
[13] were detected by direct DNA sequencing of purified
amplicons, obtained by using IGRF and IGRR primers.
The DNA sequencing was carried out, as described above
except that primer IGRF or IGRR (Table 2) or an internal
primer (IGRS, 5'-CCGCTGATCTGAACCTAGGAAC-3')
was used as sequencing primer.
Molecular fingerprinting of EMB-resistant M. tuberculosis 
isolates
The molecular fingerprinting of EMB-resistant M. tubercu-
losis isolates was performed by genetic group analysis [23]
based on polymorphisms at katG codon 463 (katG463)
and gyrA codon 95 (gyrA95) and by touchdown double-
repetitive-element (DRE)-PCR. The presence of Arg463/
Leu463 at katG463 and Ser95/Thr95 at gyrA95 were deter-
mined by PCR-RFLP as described previously [24,25].
Briefly, the amplification of katG463  and gyrA95  DNA
regions was carried out as described above except that
primers KatG1F (5'-CCCGAGGAATTGGCCGAC-
GAGTTC-3') + KatG1R (5'-GGTGCGAATGACCTTGCG-
CAGATC-3') [24] and GYRA95F (5'-CGCAGCTACATCGA
CTATGCGATG-3') + GYRA95R (5'-GGGCTTCGGTGTAC-Annals of Clinical Microbiology and Antimicrobials 2009, 8:2 http://www.ann-clinmicrob.com/content/8/1/2
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Table 1: Clinical background, resistance patterns and demographic information of patients yielding EMB-resistant M. tuberculosis 
isolates in Kuwait
Isolate no. Year of isolation Clinical specimena Resistance patternb Patient demographics
Nationality Regionc Age (years) Sex
KE1 2000 Sputum E, H, R Indian SA 43 Male
KE2 2000 Sputum E, H, R Indian SA 45 Male
KE3 2000 Sputum E, H Egyptian ME 47 Female
KE4 2000 Sputum E, H, S Indian SA 27 Male
KE5 2000 Sputum E, H Indian SA 42 Male
KE6 2000 Pus E, H Sri Lankan SA 27 Male
KE7 2000 Abscess E, H Pakistani ME 55 Male
KE8 2000 Sputum E, H, S Kuwaiti ME 45 Male
KE9 2000 Pus E, H, S Indian SA 45 Female
KE10 2000 Sputum E, H Bangladeshi SA 40 Female
KE11 2001 Sputum E, H Filipino SEA 35 Female
KE12 2001 Sputum E, H Indian SA 22 Male
KE13 2001 Sputum E, H, R Indian SA 47 Male
KE14 2001 Sputum E, H, R, S Indian SA 27 Female
KE15 2001 Sputum E, H, R, S Indian SA 32 Male
KE16 2001 FNA E, H Indian SA 27 Female
KE17 2001 Sputum E, H Indian SA 30 Male
KE18 2001 LN E, H Filipino SEA 31 Male
KE19 2001 Sputum E, H Indian SA 45 Male
KE20 2001 Sputum E, H Egyptian ME 49 Male
KE21 2001 Sputum E, H, S Indian SA 25 Male
KE22 2001 Sputum E, H, R, S Egyptian ME 27 Female
KE23 2002 Sputum E Kuwaiti ME 65 Male
KE24 2002 Sputum E, H Egyptian ME 45 Male
KE25 2002 Pus E, H Kuwaiti ME 34 Male
KE26 2002 FNA E, S Indian SA 21 Male
KE27 2002 Pus E Indian SA 30 FemaleAnnals of Clinical Microbiology and Antimicrobials 2009, 8:2 http://www.ann-clinmicrob.com/content/8/1/2
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CTCATCGCC-3') [25], respectively, were used. The puri-
fied  katG463  region amplicons were digested with
restriction enzyme Nci I to obtain RFLP patterns. The reac-
tion mixture in a final volume of 25 μl contained 2.5 μl of
BRL Buffer 8 (Gibco-BRL), 5 μl of amplicon, 2 μl (10
units) of Nci I (Gibco-BRL), and 15.5 μl of sterile water.
After incubation at 37°C for 4 h, the digested products
were separated on 2.5% agarose gels. The amplicon from
M. tuberculosis H37Rv as well as M. tuberculosis strains con-
taining Arg at katG463 (katG463CGG) yield two fragments
of 187 bp and 173 bp while the amplified fragment from
isolates containing Leu at katG463 (katG463CTG) yield
KE28 2002 BAL E, H Bangladeshi SA 32 Male
KE29 2002 GS E, R Syrian ME 57 Female
KE30 2002 Sputum E, H, R, S Nepalese SA 23 Female
KE31 2002 FNA E Indian SA 31 Male
KE32 2002 Sputum E Kuwaiti ME 25 Female
KE33 2002 Sputum E, H Pakistani ME 38 Male
KE34 2002 Sputum E, H Filipino SEA 27 Female
KE35 2002 Sputum E Indian SA 29 Male
KE36 2003 LN E Yemani ME 31 Male
KE37 2003 Pus E Kuwaiti ME 23 Male
KE38 2003 FNA E, H, S Pakistani ME 23 Male
KE39 2003 Sputum E Indian SA 26 Male
KE40 2003 FNA E Indian SA 30 Male
KE41 2003 Sputum E, H Kuwaiti ME 18 Female
KE42 2003 LN E, H Indian SA 25 Female
KE43 2003 FNA E, H Kuwaiti ME 37 Male
KE44 2003 Sputum E, H Pakistani ME 54 Male
KE45 2003 PF E, H Indian SA 45 Male
KE46 2003 Sputum E, H, R, S Indian SA 47 Male
KE47 2003 Pus E, H, R, S Iranian ME 35 Male
KE48 2003 Sputum E, H, R, S Egyptian ME 24 Male
KE49 2003 FNA E, H, R, S Egyptian ME 65 Female
KE50 2003 PF E, H Indian SA 46 Male
aFNA, fine needle aspirate; LN, lymph node; BAL, bronchoalveolar lavage; GS, gastric secretion; PF, pleural fluid
bE, ethambutol; H, isoniazid; R, rifampicin; S, streptomycin
cSA, South Asia; ME, Middle East; SEA, Southeast Asia
Table 1: Clinical background, resistance patterns and demographic information of patients yielding EMB-resistant M. tuberculosis 
isolates in Kuwait (Continued)Annals of Clinical Microbiology and Antimicrobials 2009, 8:2 http://www.ann-clinmicrob.com/content/8/1/2
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the original undigested fragment of 360 bp [24]. The puri-
fied gyrA95 region amplicons were digested with restric-
tion enzyme Ale I to obtain RFLP patterns. The reaction
mixture in a final volume of 25 μl contained, 2.5 μl of NE
Buffer 4, 1.25 μl of 10× BSA (New England Biolabs), 6.0
μl of the amplified DNA, 1 μl (5 units) of Ale I and 14.25
μl of sterile water. After incubation at 37°C for 3 h, the
digested products were separated on 2.5% agarose gels.
The amplicon from M. tuberculosis H37Rv as well as M.
tuberculosis strains containing Ser at gyrA95 (gyrA95AGC)
yield the original undigested fragment of 322 bp while the
amplified fragment from isolates containing Thr at gyrA95
(gyrA95ACC) yield two fragments of 212 bp and 110 bp
[25].
The typing of EMB-resistant M. tuberculosis isolates was
performed by touchdown DRE-PCR as described previ-
ously [26]. Briefly, the reaction mixtures in a final volume
of 50 μl contained 1× Perkin-Elmer PCR buffer II, 2.5 mM
MgCl2, 10 pmol each of the four primers (IS6110-5'R, 5'-
GGCTGAGGTCTCAGATCAGAG-3'; IS6110-3'F, 5'-
ACCCCATCCTTTCCAAGAACT-3'; PGRS-5'R, 5'-
TCCCCGCCGTTGCCGTACAG-3' and PGRS-3'F, 5'-CTT-
GGGAAACCCGGCCAGCTG-3') [26], 2 μl of template
DNA, 0.2 mM dNTPs and 2 units of AmpliTaq DNA
polymerase. The cycling parameters were same as
described previously [26]. The amplified products (20 to
25 μl) were resolved on 2% agarose gels. The M. tuberculo-
sis isolates belonging to different genetic groups and/or
yielding unique patterns of DNA amplified fragments in
DRE-PCR were considered as genotypically distinct
strains.
Nucleotide sequence accession numbers
The DNA sequencing data for the mutant strain reported
in this study have been deposited in EMBL under the
accession number AJ973188.
Results and Discussion
A total of 50 EMB-resistant strains of M. tuberculosis were
isolated from 50 different TB patients throughout Kuwait
during the year 2000 to 2003 and all the isolates were
included for analysis. Twenty of these isolates were from
patients of Middle-Eastern origin (including seven
Kuwaiti nationals), 27 from patients of South-Asian ori-
gin and three from patients of Southeast Asian countries
(Table 1). All the isolates were recovered from HIV-nega-
tive adult TB patients (18 to 65 years) and included 15
female and 35 male patients. The clinical specimens yield-
ing these strains included sputum (n = 29), pus (n = 6),
fine needle aspirate (n = 7), lymph node (n = 3), pleural
fluid (n = 2), abscess (n = 1), bronchoalveolar lavage
(BAL) (n = 1), and gastric secretion (n = 1) (Table 1). In
addition, 25 pansusceptible clinical M. tuberculosis isolates
were also included in the study. Nine, 12 and four of these
isolates were from patients of Middle-Eastern (including
three Kuwaiti nationals), South Asian, and Southeast
Asian origin, respectively. The clinical specimens yielding
pansusceptible strains included sputum samples (n = 15),
pus (n = 6), fine needle aspirate (n = 3), and tissue biopsy
(n = 1). The data are consistent with previously reported
observations that majority (~80%) of M. tuberculosis infec-
tions in Kuwait occur in foreign-born expatriate workers
mostly within the first few years of their migration even
though all expatriates entering Kuwait are screened for TB
(chest radiograph) as well as for HIV infection [9,27].
Table 2: Primer sequences and their locations in target genes used for PCR amplification of iniA501 and embC-embA IGR
Primer pair Primer name Primer sequence Target genea Directionb/position Target region Amplicon size (bp) Mutations detected 
by
1 INIAF 5'-
CGCTGGGCCGGA
TGGAATCGAA-3'
iniA F, 1403–1424 Codon 501 241 Hpy 99 I RFLP
INIAR 5'-
ACGAAGCGCCGC
ACATTGGCCTT-3'
R, 1643–1621
2I G R F 5 ' -
GTTACAGCGGTT
GACGCCTTACTA-
3'
IGRc F, 29061–29084 -11 to -43d 261 Sequencing
IGRR 5'-
CGATTCCCGAGA
CGACGGCTGCTA-
3'
R, 29321–29298
aThe accession numbers for target genes are iniA, Z95324; embC-embA IGR, AL123456
bF, forward; R, reverse
cIGR, he embC-embA intergenic region
d-11 to -43 corresponds to -11, -12, -16 and -43 positions (relative to the start codon of embA) in embC-embA IGRAnnals of Clinical Microbiology and Antimicrobials 2009, 8:2 http://www.ann-clinmicrob.com/content/8/1/2
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Only nine of 50 (18%) EMB-resistant strains were
monoresistant to EMB while the remaining (41 of 50,
82%) isolates were additionally resistant to at least one
more first-line drug. Most (39 of 41) of the latter isolates
were resistant to isoniazid with or without additional
resistance to other drugs. Twenty-four (48%) M. tuberculo-
sis strains were resistant to two drugs while eight (16%)
isolates were resistant to three drugs (including three
MDR-TB strains). Only eight (16%) EMB-resistant strains
were also resistant to the other three first-line drugs. All
the isolates were resistant to EMB on first isolation indi-
cating that the patients were already infected with EMB-
resistant strains. Furthermore, nearly same number (9 of
50, 18% and 11 of 50, 22%) of EMB-resistant M. tubercu-
losis strains were resistant to EMB alone or EMB together
with additional resistance to rifampicin and isoniazid
(MDR-TB strains). Worldwide, monoresistance to EMB is
rare and majority of EMB-resistant strains particularly
those originating from TB endemic countries are MDR-TB
strains [8,17,28].
The PCR amplification of iniA501 DNA region from 25
pansusceptible and 50 EMB-resistant M. tuberculosis
strains yielded an amplicon of 241 bp, as expected. The
Hpy 99 I digestion patterns of purified amplicons showed
that all the 25 pansusceptible and 49 EMB-resistant strains
contained TCG at iniA501 (iniA501TCG) while only one
EMB-resistant strain contained a mutated iniA501. The
results of PCR-RFLP for three pansusceptible strains con-
taining iniA501TCG, three EMB-resistant strains also con-
taining  iniA501TCG  and one EMB-resistant strain
containing a mutated iniA501 were confirmed by DNA
sequencing. The solitary isolate with a mutation at
iniA501 contained iniA501TGG (Table 3). Likewise, the
PCR amplification of DNA region encompassing embC-
embA IGR from 25 pansusceptible and 50 EMB-resistant
M. tuberculosis strains also yielded an amplicon of 261 bp,
as expected. Direct DNA sequencing of the purified ampli-
cons showed that all the 25 pansusceptible and 50 EMB-
resistant strains contained wild-type sequences including
nucleotide positions -11, -12, -16 and -43 [12] relative to
the translational start point for embA gene (Table 3). The
repeat isolates recovered from eight TB patients yielded
the same resistance pattern and the same results for
iniA501 and embC-embA IGR analyses as the parent isolate
(data not shown).
Consistent with previously reported data showing that
majority of rifampicin-resistant and isoniazid-resistant M.
tuberculosis infections in Kuwait occur in foreign-born TB
patients as a result of reactivation of previously acquired
infection [21,29,30], genetic group analysis and finger-
printing patterns obtained in DRE-PCR showed that
majority of EMB-resistant M. tuberculosis strains were also
unique strains (data not shown).
Majority (~70%) of EMB-resistant M. tuberculosis strains
from several geographical locations around the world
have been shown to contain mutations within embB gene
particularly at embB306, embB406 and embB497 [14-17].
However, in most of these studies, all or consecutive EMB-
susceptible and EMB-resistant M. tuberculosis strains from
a single location and/or isolated over a specified period of
time were not included and the proportion of MDR-TB
strains or strains resistant to several anti-TB drugs was
unusually high [15-17]. When the 50 phenotypically doc-
umented EMB-resistant M. tuberculosis strains used in this
study were tested for genotypic resistance detection target-
ing mutations at embB306, embB406 and embB497, only
38% (19 of 50) isolates contained a resistance conferring
mutation [17]. These findings suggested that mutations at
other codon positions within embB gene or in other loci
are responsible for conferring resistance to EMB in major-
ity of EMB-resistant M. tuberculosis strains in Kuwait and
their identification will be crucial for the development of
a molecular screen for rapid detection of majority of EMB-
resistant strains.
The results presented in this study showed that mutations
at iniA501 and in embC-embA IGR in EMB-resistant M.
tuberculosis strains in Kuwait also occur rather infrequently
(1 of 50, 2%). Thus, their inclusion in the molecular
screen will have only minor contribution towards detec-
tion of EMB resistance in Kuwait. Only one previous study
has detected the occurrence of mutations at iniA501 and
in embC-embA IGR in EMB-resistant M. tuberculosis strains
[13]. Although the authors reported that mutations at
iniA501 and in embC-embA IGR occurred in nearly 20%
Table 3: Occurrence of mutations at iniA501 and embC-embA IGR in 25 pansusceptible and 50 EMB-resistant clinical M. tuberculosis 
strains isolated in Kuwait
Susceptibility to ethambutol No. of isolates No. of isolates with iniA501 as No. of isolates with wild-type nucleotides at -11, -12, -16 and -
43 in embC-embA IGR
Wild-type (TCG) Mutant (TGG)
Susceptible 25 25 0 25
Resistant 50 49 1 50Annals of Clinical Microbiology and Antimicrobials 2009, 8:2 http://www.ann-clinmicrob.com/content/8/1/2
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(15 of 75) of EMB-resistant strains, majority of isolates
with mutations at iniA501  and all the isolates with a
mutation in embC-embA IGR also contained other well
characterized EMB resistance-conferring mutations, par-
ticularly at embB306, embB406 and embB497 [13]. Previ-
ous studies have shown that drug-resistant M. tuberculosis
strains isolated from TB patients with limited previous
exposure to first-line anti-TB drugs usually contain single
point mutations in resistance conferring genes while
strains from previously treated patients usually contain
multiple mutations in target genes [15,18,20,31-33]. The
susceptibility of EMB-resistant strains to other first-line
drugs and the HIV status of the TB patients in the study
that analyzed mutations at iniA501  and in embC-embA
IGR was not indicated [13]. However, the presence of
mutations in two or more genes involved in EMB resist-
ance in 25% (19 of 75) EMB-resistant strains and the geo-
graphical origin of the tested isolates indicates that the
isolates were either MDR-TB strains or strains additionally
resistant to multiple first-line drugs [13]. These observa-
tions are also consistent with the role of mutations at
iniA501 and in embC-embA IGR in conferring resistance to
EMB.
The TCG to TGG mutation at iniA501 most likely confers
resistance of M. tuberculosis to EMB by altering the struc-
tural property of the encoded protein [13]. However, the
resistance conferring mechanism explaining the role of
mutations in embC-embA IGR in EMB resistance is not well
characterized. The suggestion that C to T mutations at -12
and -16 positions lead to creation of TATA box-like
sequences [13] seems less likely since these elements are
found in promoter elements while the hot-spot DNA seg-
ment is immediately upstream of the translational start
point for EmbA and putatively involves ribosomal bind-
ing site. Furthermore, other characteristic features of pro-
moter elements (such as -35 element sequences) are also
absent in the surrounding DNA region. An alternative
(titration) mechanism to explain the role of mutations in
embC-embA  IGR is summarized below and most likely
involves premature termination of some transcripts origi-
nating from embCAB  promoter before embA  and  embB
genes are transcribed. The embC-embA IGR of 85 nucle-
otides is rather long for a polycistronic bacterial mRNA. A
closer look at embC-embA IGR and N-terminal region of
embA indicates that it contains an I-shaped transcriptional
terminator typically found in mycobacteria including M.
tuberculosis [34]. The RNA transcript involving -19 to +23
nucleotides (relative to translational start site of embA)
can form a hairpin structure that is stabilized by nine G.C
pairs including the two 'C' residues (at -12 and -16 posi-
tions) that are mostly mutated in some EMB-resistant
strains [13]. Thus, mutations of -12C or -16C residues will
decrease the stability of the hair-pin structure resulting in
decreased termination of transcripts and consequently,
increased expression of embA  and  embB  encoded gene
products. These assumptions are further supported by
occurrence of nearly all the mutations in embC-embA IGR
in isolates with a mutated embB  gene. The above also
explains the absence of these mutations in EMB-resistant
M. tuberculosis isolates in Kuwait as such mutations are
more likely to occur in TB patients with previous history
of prolonged therapy with anti-TB drugs [15,18,20,31-
33].
Conclusion
In conclusion, the results presented in this study showed
that mutations at iniA501 and in embC-embA IGR in EMB-
resistant M. tuberculosis strains isolated from TB patients in
Kuwait occur infrequently. Consequently, inclusion of
mutation detection at these loci in the molecular screen
for detecting majority of EMB-resistant M. tuberculosis
strains will contribute minimally towards this goal in
Kuwait as well as, perhaps, in other countries. Further
studies from other geographical regions are clearly war-
ranted to validate our observations.
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